Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 1.00 |
| ▸ | JAK1 | P23458 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20031473 | 1.00 | NR1H2 (1.00) | NR1H2JAK1JAK2NAMPTUSP2 | |
| SCHEMBL23406722 | 1.00 | NR1H2 (1.00) | NR1H2JAK1JAK2NAMPTUSP2 | |
| SCHEMBL20936805 | 1.00 | NR1H2 (1.00) | NR1H2JAK1JAK2NAMPTUSP2 | |
| SCHEMBL2993190 | 1.00 | NR1H2 (1.00) | NR1H2JAK1JAK2NAMPTUSP2 | |
| SCHEMBL903882 | 1.00 | NR1H2 (1.00) | NR1H2JAK1JAK2NAMPTUSP2 | |
| SCHEMBL25334757 | 0.95 | NR1H2 (0.91) | NR1H2JAK1JAK2NAMPTUSP2 | |
| SCHEMBL6747273 | 0.92 | NR1H2 (0.85) | NR1H2JAK1JAK2NAMPTUSP2 | |
| SCHEMBL24694552 | 0.92 | NR1H2 (0.85) | NR1H2JAK1JAK2NAMPTUSP2 | |
| SCHEMBL25025541 | 0.87 | NR1H2 (0.77) | NR1H2JAK1JAK2NAMPTUSP2 | |
| SCHEMBL30376062 | 0.87 | NR1H2 (0.77) | NR1H2JAK1JAK2NAMPTUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577234-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2026-03-17 | — | — | US | disclosed |
| WO-2025133989-A1 | SMYD MODULATORS AND USES THEREOF | ALT-BIO PTE. LTD. (SG) | 2025-06-26 | — | — | WO | disclosed |
| US-20240116902-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2024-04-11 | — | — | US | disclosed |
| US-11820757-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820757-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820757-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230183219-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20230183218-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20230183218-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20230183218-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| EP-2409704-A2 | c-Met modulators and methods of use | Exelixis Inc. (US) | 2012-01-25 | — | — | EP | disclosed |
| US-8067436-B2 | N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death | EXELIXIS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| EP-1673085-B1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2011-11-09 | — | — | EP | disclosed |
| EP-2210607-B1 | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer | EXELIXIS INC (US) | 2011-08-17 | — | — | EP | disclosed |
| EP-2213661-B1 | c-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2011-07-20 | — | — | EP | disclosed |
| US-7977345-B2 | c-MET modulators and method of use | EXELIXIS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20110077233-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| EP-2280003-A2 | Process for preparing receptor-type kinase modulators | Symphony Evolution, Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| EP-2277867-A2 | Compounds, pharmaceutical compositions thereof and their use in treating cancer | Symphony Evolution, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20080161305-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820757-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | CHRM2, CHRM3, CHRM4 | NR1H2 455/4885JAK1 3975/4885JAK2 4051/4885 |
| US-20230183218-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM3, CHRM2, CHRM4 | NR1H2 518/4885JAK1 3243/4885JAK2 2304/4885 |
| US-20230183219-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM3, CHRM2, CHRM4 | NR1H2 498/4885JAK1 3042/4885JAK2 2464/4885 |
| US-20240116902-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM2, CHRM3, CHRM4 | NR1H2 455/4885JAK1 3975/4885JAK2 4051/4885 |
| US-20080161305-A1 | C-Met Modulators and Methods of Use | MET, HGFAC, HGF | NR1H2 4590/4885JAK1 1727/4885JAK2 656/4885 |
| US-12577234-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | CHRM3, CHRM4, CHRM2 | NR1H2 189/4885JAK1 3054/4885JAK2 3822/4885 |
| US-20110077233-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | NR1H2 4016/4885JAK1 383/4885JAK2 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.